A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis

1. Kingwell, E, Marriott, JJ, Jette, N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128.
Google Scholar | Crossref | Medline | ISI2. Baird, SM, Dalton, J. Multiple sclerosis in pregnancy. J Perinat Neonatal Nurs 2013; 27: 232–241.
Google Scholar | Crossref | Medline3. Confavreux, C, Hutchinson, M, Hours, MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.
Google Scholar4. Vukusic, S, Hutchinson, M, Hours, M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353–1360.
Google Scholar5. Langer-Gould, A, Smith, JB, Albers, KB, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 2020; 94: e1939–e1949.
Google Scholar6. Cuello, JP, Martinez Gines, ML, Kuhle, J, et al. Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. Eur J Neurol 2019; 26: 1200–1204.
Google Scholar | Crossref | Medline7. Amato, MP, Portaccio, E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 2015; 29: 207–220.
Google Scholar | Crossref | Medline8. Lopez-Leon, S, Geissbuhler, Y, Sabido, M, et al. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. J Neurol 2020; 267: 2721–2731.
Google Scholar | Crossref | Medline9. Rebif . Rebif (interferon beta-1a) European summary of product characteristics, https://www.ema.europa.eu/en/medicines/human/EPAR/rebif (2019, accessed 23 April 2020).
Google Scholar10. Avonex . AVONEX (interferon beta-1a) European summary of product characteristics, 2019, https://www.ema.europa.eu/en/medicines/human/EPAR/avonex
Google Scholar11. Betaferon . Betaferon (interferon beta-1b) European summary of product characteristics, 2019, https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon
Google Scholar12. Extavia . Extavia (interferon beta-1b) European summary of product characteristics, 2020, https://www.ema.europa.eu/en/medicines/human/EPAR/extavia
Google Scholar13. Copaxone . Copaxone (glatiramer acetate injection) summary of product characteristics, 2019, https://www.medicines.org.uk/emc/product/7046/smpc#gref
Google Scholar14. Sorensen, PS, Koch-Henriksen, N, Petersen, T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014; 261: 1170–1177.
Google Scholar15. Krysko, KM, Rutatangwa, A, Graves, J, et al. Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis. JAMA Neurol 2020; 77: 327–338.
Google Scholar | Crossref | Medline16. Higgins, JPT, Green, S. Cochrane handbook for systematic reviews of interventions, v5.1.0. London: The Cochrane Collaboration, 2011.
Google Scholar17. Wells, G, O’Connell, D, Peterson, J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2014, accessed 20 May 2016).
Google Scholar18. Alroughani, R, Ahmed, S, Elsherbeny, D, et al. The use natalizumab in multiple sclerosis is safe and prevents disease reactivation. Neurology 2019; 92: P4.2093.
Google Scholar19. Alroughani, R, Akhtar, S, Zeineddine, M, et al. Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord 2019; 34: 9–13.
Google Scholar | Crossref | Medline20. Amato, M, Portaccio, E, Tortorella, C, et al. Disease re-activation during pregnancy after natalizumab suspension in patients with multiple sclerosis. J Neurol Sci 2015; 357: e297.
Google Scholar | Crossref | Medline21. Berenguer-Ruiz, L, Gimenez-Martinez, J, Palazon-Bru, A, et al. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. J Neurol 2019; 266: 2512–2517.
Google Scholar | Crossref | Medline22. Bsteh, G, Algrang, L, Hegen, H, et al. Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria. Mult Scler 2020; 26: 69–78.
Google Scholar | SAGE Journals | ISI23. Cuello, JP, Salgado Camara, P, Garcia Dominguez, JM, et al. Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study. Med Clin 2020; 154: 214–217.
Google Scholar | Crossref | Medline24. Esters, N, Spicher, C, Thiel, S, et al. Disease activity and disability after natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis. Neurology 2018; 90: P4.358.
Google Scholar25. Fragoso, YD, Boggild, M, Macias-Islas, MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013; 115: 154–159.
Google Scholar | Crossref | Medline | ISI26. Hellwig, K, Haghikia, A, Rockhoff, M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247–253.
Google Scholar | SAGE Journals | ISI27. Hellwig, K, Haghikia, A, Gold, R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17: 958–963.
Google Scholar | SAGE Journals | ISI28. Hemat, S, Thiel, S, Gold, R, et al. Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. Mult Scler 2018; 24: 74–75.
Google Scholar29. Herbstritt, S, Gold, R, Hellwig, K. ‘Injectables’ during pregnancy in women with multiple sclerosis. Mult Scler 2015; 23: 112–113.
Google Scholar30. Kleerekooper, I, van Kempen, ZLE, Leurs, CE, et al. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm 2018; 5: e424.
Google Scholar | Crossref | Medline31. Pardo, K, Katorza, E, Ziv-Baran, T, et al. Does use of disease modified therapies for multiple sclerosis affect fertility and pregnancy outcomes? Mult Scler 2018; 24: 509–510.
Google Scholar32. Portaccio, E, Moiola, L, Martinelli, V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks. Neurology 2018; 90: e832–e839.
Google Scholar | Crossref | Medline33. Thiel, S, Langer-Gould, A, Rockhoff, M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016; 22: 801–809.
Google Scholar | SAGE Journals | ISI34. Hemat, S, Hellwig, K, Houtchens, M, et al. Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. Neurology 2018; 90: P5.032.
Google Scholar35. Alroughani, R, Alowayesh, MS, Ahmed, SF, et al. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018; 90: e840–e846.
Google Scholar | Crossref | Medline36. Beaber, BE, Chi, MD, Brara, SM, et al. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J 2014; 18: 9–13.
Google Scholar | Crossref | Medline37. Hellwig, K, Rockhoff, M, Herbstritt, S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol 2015; 72: 1132–1138.
Google Scholar | Crossref | Medline | ISI38. Hughes, SE, Spelman, T, Gray, OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014; 20: 739–746.
Google Scholar | SAGE Journals | ISI39. Jesus-Ribeiro, J, Correia, I, Martins, AI, et al. Pregnancy in multiple sclerosis: a Portuguese cohort study. Mult Scler Relat Disord 2017; 17: 63–68.
Google Scholar | Crossref | Medline40. Manieri, MC, Mahlanza, TD, Houtchens, M. Disease-modifying therapies, fertility and post-partum multiple sclerosis course: interim data from PREG-MS cohort. Mult Scler 2018; 24: 352.
Google Scholar41. Popova, E, Boyko, A. Retrospective analysis of the effect of pregnancy on the course of multiple sclerosis in Russia. J Neurol Sci 2015; 357: e300.
Google Scholar | Crossref | Medline42. Portaccio, E, Ghezzi, A, Hakiki, B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77: 145–150.
Google Scholar | Crossref | Medline | ISI43. Portaccio, E, Ghezzi, A, Hakiki, B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845–850.
Google Scholar | Crossref | Medline44. Vukusic, S, Durand-Dubief, F, Benoit, A, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 2015; 21: 953–955.
Google Scholar | SAGE Journals | ISI45. Sahebi Vaighan, N, Ghozat, R, Abadi, A, et al. The effect of exclusive breastfeeding on postpartum multiple sclerosis relapses. Mult Scler 2017; 2017: 705–706.
Google Scholar46. Kerbrat, A, Le Page, E, Leray, E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98–102.
Google Scholar | Crossref | Medline | ISI47. Vukusic, S, Marignier, R. Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol 2015; 11: 280–289.
Google Scholar | Crossref | Medline48. Howie, PW, McNeilly, AS. Breast-feeding and postpartum ovulation. IPPF Med Bull 1982; 16: 1–3.
Google Scholar | Medline49. Datta, P, Ciplea, AI, Rewers-Felkins, K, et al. Cladribine transfer into human milk: a case report. Mult Scler J 2021; 27: 799–801.
Google Scholar | SAGE Journals | ISI50. Proschmann, U, Thomas, K, Thiel, S, et al. Natalizumab during pregnancy and lactation. Mult Scler J 2017; 24: 1627–1634.
Google Scholar | SAGE Journals51. Interferon beta . In: Drugs and Lactation Database (LactMed). Bethesda, MD: National Library of Medicine (US), 2006, https://www.ncbi.nlm.nih.gov/books/NBK501168/
Google Scholar52. Ciplea, AI, Datta, P, Rewers-Felkins, K, et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord 2020; 13: 1756286420968414.
Google Scholar | SAGE Journals

留言 (0)

沒有登入
gif